Among these, the novel IdyllaTM GeneFusion assay, a rapid and fully automated platform able to simultaneously detect ALK, ROS1, RET and NTRK1/2/3 and MET ex14 skipping mutations, is emerging and deserves validation as a stand-alone test for laboratories lacking NGS facilities or as an alternative option for ultra-rapid NSCLC patient profiling when time efficient NGS evaluation is not possible. This evidence concerns the gene RET and non-small cell lung carcinoma.